$CYTR: GREAT NEWS just announced, read between the
Post# of 22755
Steven A. Kriegsman, Chairman and CEO of CytRx says:
"It is an exciting time to be joining the CytRx Board. Aldoxorubicin is a novel therapeutic that preferentially releases drug within a tumor, and it has shown impressive results in several oncology clinical trials and has noteworthy potential in various cancer types where there is a huge unmet need, " said Ms. Cohen. "I am delighted to be able to bring my commercial expertise to the CytRx Board to help the company navigate the planned commercial launch of aldoxorubicin in 2017, and to create long term value for shareholders. "
http://www.prnewswire.com/news-releases/chery...03910.html